Evidence map›Paper›PMID 32461193›Full record

ArticleClinical immunology (Orlando, Fla.)2020

Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.

Aristo Vojdani, Datis Kharrazian

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 357 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
357citing papers in PubMed, 10 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

357 citing papers in PubMed, 10 syntheses or guidelines pooled it, 580 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

297 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Aristo VojdaniImmunosciences Lab, Inc, 822 S. Robertson Blvd, Ste. 312, Los Angeles, CA 90035, USA; Department of Preventive Medicine, Loma Linda University, Loma Linda, CA 92350, USA. Electronic address: drari@msn.com.
Datis KharrazianDepartment of Preventive Medicine, Loma Linda University, Loma Linda, CA 92350, USA; Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA. Electronic address: datis56@gmail.com.
Harvard University · USLoma Linda University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PandemicsAntibodies, ViralAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmunityBetacoronavirusCoronavirus InfectionsCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 VaccinesCross ReactionsGene ExpressionHost-Pathogen InteractionsHumansImmunity, InnateAntibodies, ViralAutoantibodiesAutoantigensCoronavirus Nucleocapsid ProteinsCOVID-19 Vaccinesnucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteinsPulmonary Surfactant-Associated ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines

Identifiers

PMID32461193
PMCPMC7246018
OpenAlexW3028098130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.